Bartlett & CO. Wealth Management LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD

Bartlett & CO. Wealth Management LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,874 shares of the biopharmaceutical company’s stock after acquiring an additional 392 shares during the quarter. Bartlett & CO. Wealth Management LLC’s holdings in Gilead Sciences were worth $873,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in GILD. Vanguard Group Inc. grew its holdings in Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after buying an additional 1,942,433 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Gilead Sciences by 12.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after acquiring an additional 1,520,809 shares during the period. Nuveen LLC purchased a new position in Gilead Sciences during the first quarter valued at approximately $620,415,000. Finally, National Pension Service increased its holdings in Gilead Sciences by 6.9% during the 1st quarter. National Pension Service now owns 3,473,373 shares of the biopharmaceutical company’s stock worth $389,191,000 after acquiring an additional 223,171 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on GILD. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a research note on Tuesday, August 19th. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the company from $108.00 to $127.00 in a report on Friday, August 8th. Finally, JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $117.17.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at $18,120,661.35. This trade represents a 1.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the transaction, the insider directly owned 113,193 shares of the company’s stock, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock valued at $9,402,130 in the last quarter. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 0.1%

GILD opened at $111.15 on Thursday. Gilead Sciences, Inc. has a 12 month low of $83.10 and a 12 month high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The business’s 50-day moving average price is $114.47 and its 200-day moving average price is $109.92. The company has a market cap of $137.92 billion, a P/E ratio of 22.14, a P/E/G ratio of 0.75 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.